Oculus Innovative Granted Reclassification for Microcyn-Based Advanced Wound Management Products in Europe

By: Benzinga
Oculus Innovative Sciences, Inc. (Nasdaq: OCLS ) a healthcare company a global healthcare company that designs, manufactures and markets prescription and non-prescription products in over 20 countries, today announced that is has been granted a reclassification of the company's CE Mark for the European formulation Dermacyn™ Wound Care. The reclassification was approved by the British Standards
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.